softer finish year revenu margin
segment contribut skew neotract
said guidanc look conserv see posit top
bottom line revis throughout year remain
weaker finish segment contribut organ growth
consist report organ sale growth vs mse
impli bp momentum acceler perform quarter
mix rel prior period neotract growth
contribut total quarterli growth vs averag
segment continu exceed expect acceler across year
bp momentum acceler challeng comp
vascular anesthesia surgic segment weaker expect
mse modestli light estim due time cathet
reprocess revenu drop-off given divestitur weaker perform
intern margin miss estim bp come
short full-year guidanc mainli due asia weak distributor order
time ep line model ahead street
admittedli may reflect growth invest given ep
solid revenu visibl initi guidanc
organ cc growth iwg acquisit discuss consist
preview lrp target recent commentari although
organ growth see sever pocket conserv
embed guid
neotract growth guidanc initi begin bp
corpor rais post post
deliv bp corpor segment primari
sourc upsid last year lead rais guidanc
initi post post neotract
guidanc impli bp corpor see
conserv given target train urologist nation dtc
roll-out favor reimburs see minim competit
impact rezum manag conservat bia
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
segment track record upsid model segment growth
bp growth still like prove conserv growth would
impli bp bp upsid vs guidanc model
manta manta enter full market releas begin year
guidanc assum revenu contribut share bp
growth discuss manta key swing factor
see see doabl drive bp
ezpla complet necessari test plan
submit fda march april meet plan outcom
meet like dictat time bla submiss
manag forecast ezpla revenu guidanc
bull case scenario see ezpla come market
contribut bp growth
price tailwind posit price result bp net tailwind
growth predominantli us surgic segment point
segment growth convers suggest guidanc
incorpor price tailwind statu quo assum
could modestli conserv underli basi model
surgic segment growth howev increment point
segment growth price tailwind could drive increment bp
corpor
net neotract manta drive bp upsid alon rel guidanc
therefor see organ growth like year model
impli organ expect upsid throughout year
remain street ep ep guidanc
y/i modestli street midpoint compar
growth note underli basi adjust tariff fx
steril etc underli ep growth manag forese
sever headwind ep includ fx coronaviru
steril impli underli ep growth
gross margin guidanc bp expans
primarili driven favor mix neotract intervent vascular
manufactur improv restructur program ebit margin guidanc
impli bp y/i expans key driver
gross margin drop-through opex leverag discuss see
top-line upsid like note point top-line upsid drive
ep bp note past year beaten initi midpoint
ep guidanc averag bp expect similar dynam
model ep y/i remain comfort
word oem acquisit februari acquir iwg high
perform conductor privat held manufactur ultra-fin wire
tube compon sale like competit process
oem busi primari focu area investor recent
commentari ceo liam kelli allud heighten
segment see cc growth guidanc emb bp
inorgan contribut iwg impli revenu within
market acquisit sustain hsd dd growth
next year accret oem segment corpor growth
rate gm om transact
modestli dilut corpor gross margin consist broader oem
segment accret ebit margin ep immedi analysi
impli see break-even cost capit
see deal gener expens earli penetr
asset profit ebit margin therefor ebitda basi
defens next year
china impact appear consist peer recent industri corpor
commentari led heighten concern around coronaviru impact china
across space particularli bd recent commentari price broader
coronaviru dynam see led concern similar potenti impact
china busi grow averag
manag forecast headwind relat coronaviru
hit quarterli revenu full year china revenu
impact assum coronaviru situat normal begin
april stabil earlier anticip ie earli march see
impact closer lower end rang note situat remain
fluid cover compani state coronaviru feedback
across coverag broader discuss coronaviru across
upsid like guidanc gener line preview
vocal surround expect upsid top
bottom line growth compani demonstr durabl perform
throughout although skew neotract upsid
expect continu given one-tim dynam play fx
steril tariff pulled-forward invest etc pressur ep growth
see greater year margin ep upsid although given
coronaviru situat steril impact expect throughout
without risk howev remain comfort guidanc street
see durabl growth mid-teen earn sustain
forese futur warrant premium valuat price target
base ep four-turn premium larg cap devic peer
see justifi given peer organ growth ep profil
price target base ep four-turn premium larg cap
devic peer see justi given outsiz organ growth margin prole
organ growth prole
maintain durabl driven
neotract vsi manta core busi
lrp margin target appear steep
variou factor includ sale mix cost
neotract growth margin potenti
greater guidanc consensu
view descript risk reward theme
investor look organ
growth acceler neotract
momentum continu manta traction
gross margin expans annual
restructur program gener busi
leverag lead pt oper
margin expans
abl drive high teen ep growth
sustain
organ growth stabil like
driven neotract core busi
stabil like drive
product mix cost program drive pt
margin lrp impli mid-teen
neotract momentum slow competit
pressur rezum intensifi
onward busi growth return
challeng organ growth
retreat mid singl digit non-underli
headwind pressur margin teleex
reach lrp target
organ growth prole acceler
neotract contribut pt growth
manta revenu translat
addit pt growth
dtd convers restructur program
drive high teen ep growth
china india
view explan region hierarchi
research highest favor quintil
neotract maintain key competit lead
mi bph market
materi margin expans driven
favor mix cost program
manta add point growth
materi delay reach
lrp margin target core busi
neotract competit intensi rezum
success take market share ofc
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million except ep
million
sale
sale
sale
sale
sale
sale
sale
sale
good sold
net incom sharehold
net incom sharehold
prepaid expens current asset
asset held sale
properti equip net
invest affili
payrol benefit-rel liabil
pension post-retir benefit
non-current liabil uncertain tax posit
addit paid capit
incom discontinu oper
amort expens intang asset
amort expens defer financ
loss extinguish debt
net loss sale busi asset
chang oper asset liabil
net provid use oper activ
expenditur properti plant equip
proce sale busi asset
payment busi intang acquir net
invest affili
net use invest activ
proce long-term borrow
repay long-term debt
increas decreas note payabl current borrow
proce stock compens
proce non-controlling interest
debt equiti issuanc amend
purchas call option
proce sale warrant
discontinu oper
net cash use provid discontinu oper
effect exchang rate ce
net chang
equival bop
equival eop
